Several RNA tumor viruses cause leukemia after inoculation into mice. The Abelson leukemia virus (A-MuLV) 1 (1) causes a rapidly progressive lymphoid leukemia, originating in the bone marrow or lymph nodes. In addition, A-MuLV quantitatively induces a leukemic transformation of hematopoietic cells in vitro (2, 3) . The leukemic cells isolated in vivo or in vitro have the properties of neither mature T nor B cells (4) , and are perhaps best classified as null cells. The Kirsten sarcoma virus (KiSV) causes an erythroid leukemia (5) .
A-MuLV and KiSV quantitatively transform NIH/3T3 cells allowing an accurate determination of virus titer. Both viruses are defective and require a competent helper virus to replicate. Viral transformed nonproducer NIH/3T3 cells free of helper virus have been isolated (5, 6) . Replicating defective virus can be rescued from these cells aRer superinfection with a competent helper virus. The super-infecting helper virus determines the pseudotype (tropism and envelope glycoprotein antigens) of the defective virus. The replication of RNA tumor viruses is restricted by the Fv.1 locus of the mouse. Two codominant genetic alleles, and Fv-lb, determine susceptibility to infection by RNA tumor viruses. Fv-l,, mice are susceptible to infection by N-or NB-tropic viruses but are resistant to B-tropic viruses, while Fv-1 ~ mice are susceptible to B-or NB-tropic viruses but are resistant to N-tropic viruses (7, 8) .
I have rescued A-MuLV and KiSV from nonproducer cells with several helper viruses to study the effect of virus pseudotype on leukemogenesis. I found that the helper virus profoundly affects the incidence of erythroid leukemia caused by KiSV and the lymphoid leukemia caused by A-MuLV. The helper virus also influences the efficiency of A-MuLV-induced in vitro transformation of hematopoietic cells. The effect of the helper virus is independent of the Fv-1 locus of the mouse. (14) isolated from the spleen of a normal elderly BALB/c mouse was a gift of Dr. P. Jolicoeur, M.I.T.
Materials and Methods
To obtain stocks of KiSV or A-MuLV as pseudotypes with different helper viruses, a clonal isolate of KiSV-transformed NIH/3T3 cells (5), or a clonal isolate of A-MuLV-transformed NIH/ 3T3 cells (ANN-l) (6) was infected with various N-or NB-tropic helper leukemia viruses. About 106 KiSV-or A-MuLV-transformed nonproducer cells were infected with a competent helper virus in the presence ofpolybrene (4 ~g/ml) (Aldrich Chemical Co., Inc., Milwaukee, Wis.). Media was collected 1 wk later and passed through a 0.45-~m filter (Nalge Co., Nalgene Labware Div., Rochester, N.Y.). The titer of the defective transforming virus, expressed as focus-forming units per ml (FFU/ml), was determined on NIH/3T3 cells (5, 6) . The cells were then ultravioletirradiated and overlaid with XC cells to determine the titer of helper virus (15) , expressed as plaque-forming units per ml (PFU/ml). The NIH/3T3 and XC cells were grown in Dulbecco's modified Eagle's medium containing 10% calf serum (Colorado Serum Co. Denver, Colo.) at 37°C in a humidified atmosphere containing 10% CO2.
Mice. C57/L (Fv-l"") and DBA/2De (Fv-l"") mice were purchased from The Jackson Labora° tory (Bar Harbor, Maine), while Swiss mice (CD-1) (Fv-l"") were purchased from Charles River Breeding Laboratories (Wilmington, Mass.). The Swiss mice were bred randomly, while the inbred strains were maintained by brother-sister crosses.
Induction of Erythroid Leukemia. Newborn Swiss mice were inoculated intraperitoneally with 0.1 ml of filtered virus stock. 3-4 wk later, the animals were killed and autopsied. Spleens were sectioned sagitally and touch preparations were made and treated with Wright-Giemsa stain. Animals with erythroblastic leukemia had grossly enlarged spleens which often ruptured, causing the death of the animal. More than 30% of the cells in areas of erythroid leukemia were proerythroblasts or basophilic erythroblasts, and occasional trinucleate forms were seen (5) . The leukemia could be induced in hypertransfused mice.
To assay for the replication of KiSV, spleens were shredded through a wire grid and a 10% (wt/ vol) cell suspension was made in medium. After removing the cells by low-speed centrifugation, the supernate was passed through a 0.45-~m membrane filter and assayed on NIH/3T3 cells (5).
Induction of Abelson Leukemia. Newborn Swiss or DBA/2 mice were inoculated with 0.1 ml of filtered virus stock. The animals were examined daily for the presence of enlarged lymph nodes, cranial tumors, or paralysis. Mice with these findings were killed and autopeied. Animals scored as having Abelson leukemia had gross and histologic evidence of lymphoblastic infiltration of the marrow, lymph nodes, and/or meninges with no involvement of the thymus (1).
Abelson Virus-Induced Hematopoietic Cell Transformation. The femoral bone marrow cells from 1 to 2-mo-old C57/L mice were collected in RPMI 1640 medium (Grand Island Biological Co., Grand Island, N.Y.) containing 20% heat (56°C) inactivated fetal calf serum, and 5 × 10 -5 M 2-mercapteethanol. The nucleated cells were diluted to 1 × 106 cells/ml and polybrene was added to a concentration of 2 ~g/ml. The filtered virus stock (0.5 ml) was added to 1.5 ml of cell suspension and incubated at 37°C for 3 h. The cells were collected by low speed centrifugation (175 g) for 15 rain and resuspended in RPMI 1640 medium containing 20% heat inactivated fetal calf serum, 5 x 10 -5 M 2-mercaptoethanol, 0.3% (wt/vol) agarose (Type II; Sigma Chemical Co., St. Louis, Mo.) at a concentration of i × 106 nucleated cells/ml. The cell suspensions (1.5 ml) were added to 30-mm plastic dishes (Nunc Products, Vanguard International, Red Bank, N.J.) and incubated at 37°C in a humidified atmosphere containing 8% CO2. The cultures were fed with 1 ml of agarose medium at 5 and 10 days postinfection. Lymphoid colonies containing more than 1,000 cells were quantitated 12 days after infection.
Results

KiSVoInduced Erythroid Leukemia. KiSV was rescued from a transformed nonproducer of NIH/3T3 cells with NB-tropic M-MuLV, N-tropic F-MuLV, or
N-tropic N35-MuLV and the titer of KiSV and helper virus were determined on NIH/3T3 cells. Virus stocks were inoculated into newborn Fv-1 nn CD-1 Swiss mice, a strain susceptible to KiSV-induced erythroid leukemia. 3-4 wk later, the animals were killed and their spleens were removed and examined to detect erythroid leukemia (5) .
Unlike Friend virus (SFFV[F-MuLV]) (11), KiSV does not induce clearly defined foci of erythroid leukemia that can be counted grossly (5) . To quantitate the leukemogenic activity of the KiSV, the incidence of erythroid leukemia was correlated with the number of FFU inoculated. It was found that approximately 102 FFU of KiSV(M-MuLV) or 103 FFU of KiSV(F-MuLV) induced erythroid leukemia in 50% of the mice (Fig. 1) . As much as 105 FFU of KiSV(N35-MuLV), however, was required to induce leukemia in 50% of the mice, demonstrating that the induction of leukemia by the N35-MuLV pseudotype of KiSV was far less efficient. The helper viruses alone did not induce erythroid leukemia. The helper virus does, however, determine the efficiency of leukemogenesis induced by KiSV. This effect appears to be independent of the Fv-1 locus, since the Fv-1"" Swiss mice used in these experiments are susceptible to leukemogenesis induced by N-tropic KiSV(F-MuLV).
Recovery of KiSV from the Spleens of Leukemic and Non-Leukemic Mice.
It is possible that the intraperitoneal inoculum of KiSV did not reach the spleens of the non-leukemic mice. To learn if KiSV was present in the spleens of these mice, the spleens of both leukemic and non-leukemic mice were assayed for the presence of virus. Replicating KiSV could be recovered from the spleens of both leukemic and non-leukemic animals inoculated with either KiSV(F-MuLV) or KiSV(N35-MuLV) (Table I ), but not from mice infected with helper virus alone (5). Thus, the KiSV replicated in the spleen cells of the non-leukemic animals. Since spleens contain a heterogenous group of cells, it is possible that the erythroid precursors of non-leukemic animals were not infected with KiSV.
Although KiSV replicated in the spleens of the non-leukemic animals, the titer of KiSV and helper virus (F-MuLV or N35-MuLV) was approximately 100-fold higher in the spleens of the leukemic animals. This increased titer of virus in the leukemic mice probably reflects the replication of leukemia cells. The murine genetic locus, Fv-1, restricts the replication of competent helper viruses. Restriction is dominant and appears to act after virus absorption and penetration (17, 18) . The pseudotype of a defective agent, including its N-or Btropism, is determined by the helper virus (19) . The Fv-1 locus can restrict both the sarcoma virus-induced transformation of fibroblasts in vitro (19) , and SFFV-induced erythroid leukemia in vivo (8) . In the present study Fv-1 nn hosts were infected with N-or NB-tropic pseudotypes of defective viruses. The viruses were grown and titered on FV-1 nn NIH/3T3 cells. However, these virus stocks varied widely in their ability to induce leukemia. Clearly the Fv-1 ~ phenotype is not responsible for the observed restriction of leukemogenic activity.
A-MuLV-Induced Lymphoid
The Effect of the Helper Virus on the Frequency of A-MuLV-Induced Bone Marrow Cell Transformation in Fv-l"" C57/L Mice
There are two classes of murine ecotropic helper viruses. The endogenous viruses, typified by N35-MuLV, are integrated into the host's germ line, and are inherited in a vertical fashion. These viruses may begin to replicate in elderly mice and can often be induced to replicate in cells in vitro, after the addition of halogenated pyrimidines (20) . Inoculation of endogenous viruses into susceptible mice may result in the formation of tumors, but these tumors usually apear at low frequency after a prolonged latent period that is often greater than 1 yr (21) . The exogenous viruses, typified by F-MuLV, M-MuLV, and R-MuLV (FMR group), are usually not inherited vertically (22) . Inoculation of helper FMR viruses into mice results in a high frequency of lymphoid tumors with a shorter latent period (11/2-6 mo). The present study shows that an FMRpseudotype of either A-MuLV or KiSV induces leukemia far more efficiently than an N35-MuLV endogenous virus pseudotype of these two defective transforming viruses. In addition, a Ki-MuLV pseudotype of A-MuLV does not induce Abelson leukemia. Ki-MuLV shares common envelope and p12 antigens with the endogenous viruses (13) . Thus, mice appear to be able to restrict leukemia induced by endogenous viruses alone, and leukemia induced by an endogenous virus pseudotype of a defective transforming virus.
Virus spread may contribute to the induction of leukemia in vivo by either AMuLV or KiSV. Certainly, the titer of KiSV present in the spleens of nonleukemic animals is lower than the titer in leukemic animals (Table I ). In addition, an endogenous virus pseudotype of A-MuLV, that does not induce leukemia in vivo, cannot be recovered from the hematopoietic tissues of mice (23) .
To study a single-step leukemia transformation event, I infected bone marrow cells with pseudotypes of A-MuLV and plated the cells in a soft agarose gel. Rosenberg and Baltimore (3) have demonstrated that the number of transformed lymphoid cells recognized in this gel culture system is directly proportional to the virus inoculum (one-hit kinetics). Thus, transformation is the result of a single-step event rather than being caused by virus spread.
The A-MuLV genome appears to be responsible for inducing leukemic transformation, because nonproducer cells have been isolated. These nonproducer lymphoid cells are isolated at a low frequency (1/4) because of the presence of excess helper virus in the inoculum. Murine sarcoma virus-transformed nonproducer BALB/c-3T3 cells have been isolated at a comparable frequency (24) .
Although A-MuLV appears to contain the genetic information that controls lymphoid cell transformation, the present study shows that the helper virus also has an important role. FMR helpers allow a high frequency of transformation while the N35-MuLV endogenous virus or Ki°MuLV do not. Mixing experiments demonstrate that the addition of an effective helper such as MMuLV to stocks of poorly transforming A-MuLV (N35-MuLV) does not enhance lymphoid transformation. Since complementation does not occur, the pseudotype of A-MuLV, rather than the presence of an exogenous effective helper, controls the transformation of hematopoietic cells.
The pseudotype of A-MuLV affects its ability to transform hematopoietic cells in vitro. It is likely that the pseudotype of A-MuLV and KiSV, rather than the presence of an effective complementing helper also controls leukemogenesis in vivo. This control of leukemogenesis by the helper virus may be a general one.
N35-MuLV and Ki-MuLV pseudotypes of A-MuLV and KiSV readily transform NIH/3T3 fibroblast-like cells. However, the virus-induced leukemic change in hematopoietic cells is restricted both in vivo and in vitro. The mechanism of restriction remains unclear. One possibility is that the hematopoietic cells block an early event in the infectious cycle. 
